Is INMB or IONS more undervalued in 2026?

CirclFi compares INmune Bio Inc. (INMB) and Ionis Pharmaceuticals, Inc. (IONS) using 13 institutional-grade valuation models. INMB has a Quality of Company score of 5.7/10 while IONS scores 3.6/10.

Which is a better buy — INMB or IONS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do INMB and IONS valuations compare?

INMB at $1.42 and IONS at $77.33 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

INMB vs IONS Valuation Comparison 2026 — Intrinsic Value Analysis

INMB

Biotechnology

INmune Bio Inc.

Quality

5.7

out of 10

Value Trap

LOW

Price

$1.42

Last close

Models

9/13

Active

IONS

Biotechnology

Ionis Pharmaceuticals, Inc.

Quality

3.6

out of 10

Value Trap

SAFE

Price

$77.33

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	INMB Fair Value	INMB Upside	IONS Fair Value	IONS Upside
Bayesian DCF	Intrinsic	$0.57	-59.8%	$26.36	-65.9%
Earnings Power Value	Intrinsic	—	—	$36.24	-50.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.90	+34.0%	$10.21	-85.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for INMB vs IONS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

INMB vs IONS — Which Stock Is More Undervalued?

INMB scores higher with a 5.7/10 quality rating vs IONS's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing INmune Bio Inc. (INMB) and Ionis Pharmaceuticals, Inc. (IONS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

INMB currently trades at $1.42 with a QOC of 5.7/10, while IONS trades at $77.33 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).